Yamamoto et al. demonstrated in tumor-bearing mice that the amount of anti-PD-L1 antibody transferred into intraperitoneal tumors increased by approximately eight-fold following i.p. treatment compared with that administered intravenously, thus enhancing antitumor efficacy31. Here, CD274 is linked to neoplasm.